Shares of Atossa Genetics Inc. (NASDAQ:ATOS – Get Free Report) have been given a consensus recommendation of “Hold” by the five research firms that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a sell recommendation and three have given a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $20.3333.
ATOS has been the topic of several analyst reports. Wall Street Zen raised shares of Atossa Genetics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings restated a “sell (e+)” rating on shares of Atossa Genetics in a research report on Tuesday, September 8th. Finally, Rodman & Renshaw started coverage on Atossa Genetics in a report on Tuesday, July 7th. They issued a “buy” rating and a $12.00 price objective on the stock.
Check Out Our Latest Analysis on ATOS
Atossa Genetics Stock Performance
Atossa Genetics (NASDAQ:ATOS – Get Free Report) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.07. As a group, research analysts forecast that Atossa Genetics will post -3.95 EPS for the current fiscal year.
Institutional Trading of Atossa Genetics
An institutional investor recently bought a new stake in Atossa Genetics stock. State Street Corp purchased a new position in shares of Atossa Genetics Inc. (NASDAQ:ATOS – Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 39,761 shares of the company’s stock, valued at approximately $77,000. State Street Corp owned 0.40% of Atossa Genetics as of its most recent SEC filing. 12.74% of the stock is currently owned by institutional investors.
Atossa Genetics Company Profile
Atossa Genetics, Inc, now operating as Atossa Therapeutics, Inc (NASDAQ: ATOS), is a clinical-stage biopharmaceutical company focused on developing therapies for breast cancer and other diseases affecting breast tissue. The company’s research is centered on targeted treatments intended to address unmet needs in the prevention and treatment of breast cancer.
Atossa’s principal investigational product is oral endoxifen, a selective estrogen receptor modulator being evaluated in clinical studies involving patients with hormone receptor-positive breast cancer.
Featured Stories
- Five stocks we like better than Atossa Genetics
- Meta’s Muse Highlights Arm’s Growing Role in AI Infrastructure
- Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring
- AMD Chips Away at NVIDIA’s AI Throne
- Is the Fed Playing Chess With Rates—Or Just Behind the Curve Again?
Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
